Haemonetics (HAE) Receivables (2010 - 2026)

Haemonetics has reported Receivables for 17 years, with the latest figure at $216.9 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 7.01% year-over-year to $216.9 million; the trailing twelve-month figure through Mar 2026 stood at $216.9 million (up 7.01% YoY), and the FY2026 full-year result was $216.9 million, up 7.01% from the prior year.
• Receivables for Q1 2026 stood at $216.9 million, up from $195.7 million in the prior quarter.
• The five-year high for Receivables was $216.9 million in Q1 2026, with the low at $152.9 million in Q3 2022.
• Average Receivables over 5 years is $191.3 million, with a median of $198.2 million recorded in 2025.
• Year-over-year, Receivables increased 24.57% in 2022 and declined 7.66% in 2025.
• Tracing HAE's Receivables over 5 years: stood at $187.7 million in 2022, then climbed by 12.74% to $211.6 million in 2023, then gained by 0.16% to $211.9 million in 2024, then slipped by 7.66% to $195.7 million in 2025, then grew by 10.81% to $216.9 million in 2026.
• The last three Receivables figures came in at $216.9 million (Q1 2026), $195.7 million (Q4 2025), and $207.1 million (Q3 2025), per Business Quant data.

Peer Comparison